Will CSL shares rise in value over the next 12 months? Here's what the experts say

Can CSL have a better year in FY2025?

| More on:
Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We're now less than a week away from the end of the current financial year and the start of a new one. As such, it's a good time to take stock of some of the top ASX 200 shares on our share market and discuss what the 2025 financial year might have in store for them. Today, it's CSL Ltd (ASX: CSL) shares' turn.

The CSL share price has had a decent, if unspectacular, FY2024. This ASX 200 healthcare stock started FY2024 at $277.38 a share. Today, those same shares are trading at $293.73 at the time of writing, up 0.56% for the day thus far. This means that this company has appreciated by 5.90% over the 2024 financial year to date.

Now that's a decent return. But it hasn't been enough to make CSL a market beater (at least with three-and-a-half days of FY2024 to go). The S&P/ASX 200 Index (ASX: XJO) has risen 8.46% over the same period.

But maybe FY2025 will be a better year for CSL shares. At least that's what its shareholders would be hoping right about now. But let's see what some ASX experts are pencilling in for this healthcare giant this June.

ASX experts: CSL shares set for a great FY2025

Here at the Fool, we've looked at a few ASX expert opinions on the CSL share price over the past month or so. First up is ASX broker Macquarie. As my Fool colleague James looked at earlier this month, Macquarie analysts are highly bullish on the company right now. The broker recently gave CSL an 'outperform' rating alongside a 12-month share price target of $330 a share.

If realised, CSL would gain a rosy 12.34% or so over the 2025 financial year.

Not only that, but Macquarie sees continuing success for this ASX 200 stock. It reckons CSL shares could even climb as high as $500 each by 2027, thanks to the strength of the company's Behring business.

But Macquarie isn't the only ASX expert bullish on the CSL share price.

Earlier this month, we also looked at the views of Roy Hunter, portfolio manager at the SG Hiscock Medical Technology Fund. Hunter was asked if CSL shares could indeed hit $500 in the next few years. He replied, "absolutely", and stated this:

I think it's a fool's errand to bet against the ongoing success of a company like CSL. Its core plasma business looks set to deliver strong growth and margin expansion over the next few years.

It seems other experts share this sentiment. According to CommSec, four analysts currently have 'hold' recommendations on CSL, with a further three calling the stock a 'moderate buy', and four arguing CSL shares are a 'strong buy'.

So it seems most ASX experts are united in thinking FY2025 will be a great year for CSL shares. But let's wait and see if they're on the money here.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a woman and a man sleep side by side with the woman placing a hand on the man's chest while he wears a sleep breathing machine.
Healthcare Shares

Do weight loss drugs pose a threat to ResMed shares?

It's a question being asked amongst investor circles in 2024.

Read more »

A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
Healthcare Shares

Buy this high-flying ASX healthcare stock for market-beating returns

Bell Potter thinks this top stock could keep rising from where it trades today.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Telix share price hits record high on strong quarter and guidance upgrade

This market darling has continued to deliver stunning top line growth.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 66% in FY24, will Telix Pharmaceuticals shares continue?

After such an impressive run, has the trend exhausted?

Read more »

Man sleeping with a sleep apnoea mask on.
Healthcare Shares

Buy Resmed shares at 'attractive entry level' says top broker

Could this be the right entry point to own Resmed?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

CSL shares hit new 52-week high! What's next?

These ASX experts reckon CSL investors are still in for a treat.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

NIB shares rise as top broker calls the stock a buy

Is this stock a healthy opportunity?

Read more »

Man pointing at a blue rising share price graph.
Healthcare Shares

Why is the Nanosonics share price rocketing 10% today?

Investors are pleased with a big improvement in this company's performance.

Read more »